DoMore Diagnostics is a precision medicine company established to meet the need for novel methods to personalize cancer treatment. The company is based on prominent research from leading institutions including Oslo University Hospital, Oxford University, and University College of London. Their mission is to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes and reduce healthcare costs.

The company was selected as a Lighthouse project by the Norwegian Research Council for developing new AI-based diagnostic methods in cancer. It was initially led by Prof. Håvard Danielsen and focuses on using artificial intelligence in digital pathology to reduce over- and undertreatment in cancer. DoMore Diagnostics aims to provide objective and precise methods for cancer prognosis to optimize treatment worldwide.